Home » Topics » BioWorld Science

BioWorld Science
RSS

Deleterious telomerase mutations identified in patients with end-stage liver disease

Nov. 26, 2018

Phase III study of VR-475 in severe uncontrolled asthma does not meet primary endpoint

Nov. 26, 2018

MicuRx initiates phase II study of contezolid acefosamil in ABSSSI

Nov. 26, 2018

European Commission approves pegfilgrastim biosimilar Pelmeg

Nov. 26, 2018

Improved mouse model of type A hepatic encephalopathy devised

Nov. 26, 2018

AB-122 demonstrates preliminary safety and activity in solid tumors

Nov. 26, 2018

First-in-human data presented for FAZ-053 monotherapy or in combination with spartalizumab

Nov. 26, 2018

TAS-1553 demonstrates efficacy in preclinical models of hematological and solid tumors

Nov. 26, 2018

Arcus Biosciences patents adenosine A2A/A2B receptor antagonists

Nov. 26, 2018

Results from phase I/II study of INT230-6 in solid tumors

Nov. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...